<tei xml:space="preserve">
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        REFERENCES<lb/> 
        <bibl><label>1</label>. Canonica GW, Bousquet J, Mullol J, Scadding GK,<lb/> Virchow JC. A survey of the burden of allergic rhinitis in<lb/> Europe. Allergy 2007;62 (Suppl 85):17-25.<lb/> </bibl>
        <bibl><label>2</label>. Schatz M. A survey of the burden of allergic rhinitis in the<lb/> USA. Allergy 2007;62 (Suppl 85):9-16.<lb/> </bibl>
        <bibl><label>3</label>. Bauchau V, Durham SR. Prevalence and rate of diagnosis<lb/> of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64.<lb/> </bibl>
        <bibl><label>4</label>. Meltzer EO, Szwarcberg J, Pill MW. Allergic rhinitis,<lb/> asthma, and rhinosinusitis: diseases of the integrated air-<lb/>way. J Manag Care Pharm 2004;10:310-7.<lb/> </bibl>
        <bibl><label>5</label>. Okuda M. Epidemiology of Japanese cedar pollinosis<lb/> throughout Japan. Ann Allergy Asthma Immunol 2003;91:<lb/> 288-96.<lb/> </bibl>
        <bibl><label>6</label>. PG-MARJ Committee. [Practical Guideline for the Man-<lb/>agement of Allergic Rhinitis in Japan], 5th edn. Tokyo:<lb/> Life Science, 2005 (in Japanese).<lb/> </bibl>
        <bibl><label>7</label>. Okuda M, Ohkubo K, Goto M et al. Comparative study of<lb/> two Japanese rhinoconjunctivitis quality-of-life question-<lb/>naires. Acta Otolaryngol 2005;125:736-44.<lb/> </bibl>
        <bibl><label>8</label>. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-<lb/>effectiveness in Health and Medicine. New York: Oxford<lb/> University Press, 1996.<lb/> </bibl>
        <bibl><label>9</label>. The EuroQol Group. EuroQol-a new facility for the<lb/> measurement of health-related quality of life. Health Pol-<lb/>icy 1990;16:199-208.<lb/> </bibl>
        <bibl><label>10</label>. Monden A, Ogino S. [The evaluation of the utility values<lb/> for allergic rhinitis patients using EQ-5D]. [Journal of Ja-<lb/>pan Society of Immunology and Allergology in Otolaryngol-<lb/>ogy] 2005;23:15-8 (in Japanese).<lb/> </bibl>
        <bibl><label>11</label>. Kawaguchi T, Hoshiyama Y, Watanabe Y. [Cost of ceder<lb/> pollinosis]. Arerugi no Rinsho 2001;22:178-82 (in Japa-<lb/>nese).<lb/> </bibl>
        <bibl><label>12</label>. Okuda M. Arerugisei bien no chiryo ni ikurakakaruka.<lb/> [Allergology &amp; Immunology] 1998;5:615-20 (in Japanese).<lb/> </bibl>
        <bibl><label>13</label>. Scadding GK, Bousquet J. Introduction: allergic rhinitis.<lb/> Allergy 2007;62 (Suppl 85):3-5.<lb/> </bibl>
        <bibl><label>14</label>. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman<lb/> MF, Pashos CL. Economic impact and quality-of-life bur-<lb/>den of allergic rhinitis. Curr Med Res Opin 2004;20:305-<lb/>17.<lb/> </bibl>
        <bibl><label>15</label>. Fox-Rushby J, Carins J. Economic Evaluation. Berkshire:<lb/> Open University Press, 2005.<lb/> </bibl>
        <bibl><label>16</label>. McPake B, Kumaranayake L, Normand C. Health Eco-<lb/>nomics: An International Perspective. London: Routledge,<lb/> 2002.<lb/> </bibl>
        <bibl><label>17</label>. Buckingham K. A note on HYE (healthy years equiva-<lb/>lent). J Health Econ 1993;12:301-9.<lb/> </bibl>
        <bibl><label>18</label>. Drummond MF, Sculpher MJ, Torrance GW, O&apos;Brien BJ,<lb/> Stoddart GL. Methods for Economic Evaluation of Health<lb/> Care Programmes, 3rd edn. Oxford: Oxford University<lb/> Press, 2004.<lb/> </bibl>
        <bibl><label>19</label>. Keeny R, Raiffa H. Decisions with Multiple Objectives: Pref-<lb/>erence and Value Tradeoffs, 2nd edn. Cambridge: Cam-<lb/>bridge University Press, 1993.<lb/> </bibl>
        <bibl><label>20</label>. von Neumann J, Morgenstern O. Theory of Games and<lb/> Economic Behavior. Princeton: Princeton University<lb/> Press, 1944.<lb/> </bibl>
        <bibl><label>21</label>. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring<lb/> and Valuing Health Benefits for Economic Evaluation. Ox-<lb/>ford: Oxford University Press, 2007.<lb/> </bibl>
        <bibl><label>22</label>. Stavem K. Reliability, validity and responsiveness of two<lb/> multiattribute utility measures in patients with chronic ob-<lb/>structive pulmonary disease. Qual Life Res 1999;8:45-54.<lb/> </bibl>
        <bibl><label>23</label>. Torrance GW, Furlong W, Feeny D. Health utility estima-<lb/>tion. Expert Review of Pharmacoeconomics and Outcomes<lb/> Research 2002;2:99-108.<lb/> </bibl>
        <bibl><label>24</label>. Torrance GW. Social preferences for health states: an em-<lb/>pirical evaluation of three measurement techniques. So-<lb/>cioecon Plann Sci 1976;10:129-36.<lb/> </bibl>
        <bibl><label>25</label>. Buckingham JK, Birdsall J, Douglas JG. Comparing three<lb/> versions of the time tradeoff: time for a change? Med De-<lb/>cis Making 1996;16:335-47.<lb/> </bibl>
        <bibl><label>26</label>. Konno A, Numata T, Nagata H, Terada N. Tsuunensei<lb/> arerugi no gappei ga sugikafunsho hassho ni ataeru<lb/> eikyo. Arerugi no Rinsho 1998;18:178-81 (in Japanese).<lb/> </bibl>
        <bibl><label>27</label>. Inaba A. Problems relating to declining response rates to<lb/> social survey research in Japan: trends after 2000. Inter-<lb/>national Journal of Japanese Sociology 2007;16:10-22.<lb/> </bibl>
        <bibl><label>28</label>. Gold MR, Franks P, McCoy KI, Fryback DG. Toward con-<lb/>sistency in cost-utility analyses: using national measures<lb/> to create condition-specific values. Med Care 1998;36:778-<lb/>92.<lb/> </bibl>
        <bibl><label>29</label>. Sullivan PW, Nichol MB. The economic impact of payer<lb/> policies after the Rx-to-OTC switch of second-generation<lb/> antihistamines. Value Health 2004;7:402-12.<lb/> </bibl>
        <bibl><label>30</label>. Sullivan PW, Follin SL, Nichol MB. Transitioning the<lb/> second-generation antihistamines to over-the-counter<lb/> status: a cost-effectiveness analysis. Med Care 2003;41:<lb/> 1382-95.<lb/> </bibl>
        <bibl><label>31</label>. Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U.<lb/> Economic evaluation of a tablet-based vaccination against<lb/> hay fever in Denmark. Ugeskr Laeger 2008;170:138-42.<lb/> </bibl>
        <bibl><label>32</label>. Canonica GW, Poulsen PB, Vestenbaek U. Cost-<lb/>effectiveness of GRAZAX for prevention of grass pollen in-<lb/>duced rhinoconjunctivitis in Southern Europe. Respir Med<lb/> 2007;101:1885-94.<lb/> </bibl>
        <bibl><label>33</label>. Bachert C, Vestenbaek U, Christensen J, Griffiths UK,<lb/> Poulsen PB. Cost-effectiveness of grass allergen tablet<lb/> (GRAZAX) for the prevention of seasonal grass pollen in-<lb/>duced rhinoconjunctivitis-a Northern European per-<lb/>spective. Clin Exp Allergy 2007;37:772-9.<lb/> </bibl>
        <bibl><label>34</label>. Arnesen T, Trommald M. Are QALYs based on time<lb/> trade-off comparableï¼Ÿ-A systematic review of TTO<lb/> methodologies. Health Econ 2005;14:39-53.</bibl>
        </listBibl>
    </text>
</tei>

